News
PRTA
15.22
-4.93%
-0.79
Analysts’ Top Healthcare Picks: Brookdale Senior Living (BKD), Santhera Pharmaceuticals Holding (SPHDF)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Prothena (PRTA) and CVS Health (CVS)
TipRanks · 1d ago
Optimistic Outlook on Prothena Despite Phase 2b PADOVA Setbacks
TipRanks · 1d ago
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga · 1d ago
Demystifying Prothena Corp: Insights From 6 Analyst Reviews
Benzinga · 1d ago
Prothena Price Target Cut to $48.00/Share From $84.00 by HC Wainwright & Co.
Dow Jones · 1d ago
Prothena Price Target Announced at $40.00/Share by Chardan Capital
Dow Jones · 1d ago
Prothena Initiated at Buy by Chardan Capital
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Prothena Corp, Lowers Price Target to $48
Benzinga · 1d ago
Chardan Capital Initiates Coverage On Prothena Corp with Buy Rating, Announces Price Target of $40
Benzinga · 1d ago
Prothena initiated with a Buy at Chardan
TipRanks · 1d ago
Prothena price target lowered to $48 from $84 at H.C. Wainwright
TipRanks · 1d ago
Even after rising 16% this past week, Prothena (NASDAQ:PRTA) shareholders are still down 67% over the past three years
Simply Wall St · 1d ago
Prothena Is Maintained at Neutral by B of A Securities
Dow Jones · 2d ago
Prothena Price Target Cut to $22.00/Share From $26.00 by B of A Securities
Dow Jones · 2d ago
B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $22
Benzinga · 2d ago
RBC sees justification for Prothena rebound after study miss
TipRanks · 2d ago
Prothena price target lowered to $22 from $26 at BofA
TipRanks · 2d ago
Prothena price target lowered to $58 from $62 at Oppenheimer
TipRanks · 2d ago
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Benzinga · 2d ago
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.